Copyright
©The Author(s) 2017.
World J Gastroenterol. Jul 28, 2017; 23(28): 5187-5195
Published online Jul 28, 2017. doi: 10.3748/wjg.v23.i28.5187
Published online Jul 28, 2017. doi: 10.3748/wjg.v23.i28.5187
Table 1 Patients’ characteristics n (%)
Characteristics | P value |
Age (yr), mean ± SD (range) | 65 ± 10 (30-85) |
Gender | |
Male | 197 (58) |
Female | 145 (42) |
Length of follow-up (mo), median (IQR) | 11 (6-24) |
Venous thromboembolism | |
Pulmonary embolism | 9 (2.6) |
Deep venous thrombosis | 22 (6.4) |
Portal vein thrombosis | 2 (0.6) |
Port-a-Cath | 1 (0.3) |
Cumulative frequency | 34 (9.9) |
Khorana Class of risk | |
Low | 199 (58) |
Intermediate | 118 (35) |
High | 25 (7) |
Site of primary | |
Colon-rectum | 237 (69) |
Stomach | 38 (11) |
Pancreas | 36 (11) |
Biliary tract | 16 (5) |
Oesophagus | 15 (4) |
Stage of disease | |
Primary | 142 (42) |
Metastatic | 200 (58) |
Performance status (ECOG) | |
0 | 274 (80) |
1 | 60 (18) |
2 | 8 (2) |
Body mass index, mean ± SD (range) | 24.9 ± 4.0 (14.8-39.5) |
Normoweight | 200 (58) |
Overweight | 106 (31) |
Obese | 36 (11) |
Type 2 diabetes | 79 (23) |
Impaired glucose tolerance | 23 (7) |
Table 2 Glycemic indexes in gastrointestinal cancer patients - Comparison between patients who developed or not venous thromboembolism during chemotherapy
Whole cohort | Venous thromboembolism | P value1 | ||
Yes (n = 34) | No (n = 308) | |||
Glycemia (mg/dL), mean ± SD (range) | 107 ± 38 (51-415) | 122 ± 53 (60-339) | 105 ± 36 (51-415) | 0.019 |
Insulinemia (μIU/mL), median (IQR) | 12.5 (8.8-20.1) | 17.2 (11.9-24.5) | 11.6 (8.7-18.6) | 0.016 |
HOMA index, median (IQR) | 3.0 (2.0-5.6) | 4.8 (3.0-8.1) | 2.8 (2.0-4.9) | 0.006 |
HbA1c (%), mean ± SD (range) | 6.1 ± 0.8 (4.3-13.0) | 6.2 ± 0.6 (5.2-8.0) | 6.1 ± 0.8 (4.3-13.0) | 0.436 |
Table 3 Receiver operating characteristics and Bayesian analysis of venous thromboembolism predictive value of glycemic parameters
Fasting blood glucose | Fasting insulin | HOMA | HbA1c | |
AUC (SE) | 0.636 (0.06) | 0.630 (0.05) | 0.647 (0.05) | 0.574 (0.06) |
95%CI | 0.582-0.687 | 0.576-0.681 | 0.593-0.697 | 0.519-0.627 |
Criterion1 | 103 mg/dL | 12 μIU/mL | 2.6 | 6.0% |
Sensitivity | 75% | 75% | 81% | 59% |
Specificity | 65% | 51% | 48% | 63% |
PPV | 18% | 14% | 14% | 14% |
NPV | 96% | 95% | 96% | 94% |
+LR (CI) | 2.12 (1.54-2.57) | 1.54 (1.13-1.85) | 1.56 (1.19-1.81) | 1.60 (1.07-2.13) |
-LR (CI) | 0.39 (0.19-0.68) | 0.49 (0.23-0.87) | 0. 39 (0.16-0.78) | 0.65 (0.38-0.96) |
P value2 | 0.0135 | 0.0128 | 0.0045 | 0.1989 |
Table 4 Cox proportional hazards survival regression analysis of the predictive value of clinical-pathological variables and glycemic indexes on venous thromboembolism-free survival of gastrointestinal cancer patients n (%)
Variable | n | VTE | HR (CI) | P value | |
Yes | No | ||||
Sex | |||||
Male | 197 | 17 (9) | 180 (91) | ||
Female | 145 | 17 (12) | 128 (88) | 0.48 (0.24-0.97) | 0.040 |
Age | |||||
≤ 65 yr | 157 | 9 (6) | 148 (94) | ||
> 65 yr | 185 | 25 (14) | 160 (86) | 2.15 (0.96-4.79) | 0.062 |
Diabetes | |||||
No | 240 | 20 (8) | 220 (92) | ||
IGT | 23 | 2 (9) | 21 (91) | ||
T2D | 79 | 12 (15) | 67 (85) | 0.94 (0.62-1.41) | 0.748 |
Tumor site | |||||
Colorectal | 237 | 25 (11) | 212 (89) | ||
Stomach | 38 | 3 (8) | 35 (92) | ||
Esophagus | 15 | 2 (13) | 13 (87) | ||
Pancreas | 36 | 3 (8) | 33 (92) | ||
Biliary tract | 16 | 1 (6) | 15 (94) | 0.78 (0.53-1.14) | 0.201 |
Khorana class of risk | |||||
Low | 199 | 19 (10) | 180 (90) | ||
Intermediate | 118 | 13 (11) | 105 (89) | ||
High | 25 | 2 (8) | 23 (92) | 1.20 (0.64-2.26) | 0.562 |
Stage of disease | |||||
Primary | 142 | 9 (6) | 133 (94) | ||
Metastatic | 200 | 25 (12) | 175 (88) | 1.81 (0.75-4.33) | 0.186 |
ECOG-PS | |||||
0 | 274 | 24 (9) | 250 (91) | ||
1 | 60 | 7 (12) | 53 (88) | ||
2 | 8 | 3 (37) | 5 (62) | 2.47 (1.22-4.99) | 0.012 |
Homa index | |||||
≤ 2.6% | 155 | 7 (5) | 148 (95) | ||
> 2.6% | 187 | 27 (14) | 160 (86) | 4.13 (1.63-10.5) | 0.003 |
Bevacizumab | |||||
No | 270 | 22 (8) | 248 (92) | ||
Yes | 72 | 12 (17) | 60 (83) | 1.77 (0.74-4.25) | 0.199 |
- Citation: Guadagni F, Riondino S, Formica V, Del Monte G, Morelli AM, Lucchetti J, Spila A, D’Alessandro R, Della-Morte D, Ferroni P, Roselli M. Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer. World J Gastroenterol 2017; 23(28): 5187-5195
- URL: https://www.wjgnet.com/1007-9327/full/v23/i28/5187.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i28.5187